Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Simiao Yong'an decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences for the treatment of non-infectious uveitis. It is a modified version of the classic Simiao Yong'an decoction, which traditionally comprises four primary herbs: Lonicerae Japonicae Flos (honeysuckle), Scrophulariae Radix (figwort root), Angelicae Sinensis Radix (Chinese angelica), and Glycyrrhizae Radix et Rhizoma (licorice). The modification is specifically tailored to address the TCM syndrome of "heat toxin entering the collaterals," a pathological state associated with severe intraocular inflammation. Administered as granules, the decoction is evaluated as an adjunctive therapy to basal treatment to improve clinical outcomes and reduce the recurrence of uveitis by modulating inflammatory pathways and clearing systemic heat toxins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified Simiao Yong'an decoction.